Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy
JACC: Heart Failure · 2025-08 · 13 (8) · 102496
DOI: 10.1016/j.jchf.2025.03.040 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift JACC: Heart Failure, 2025-08. Verfasst von Sara Saberi und 26 weiteren Autor:innen. Beteiligte Einrichtung: University of Michigan, Ann Arbor, Michigan, USA. Electronic address: saberis@med.umich.edu. Hauptthemen laut MEDLINE: Cardiomyopathy, Hypertrophic. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Cytokinetics Inc.
Abstract (Originalsprache)
BackgroundLong-term safety and efficacy data for aficamten in symptomatic obstructive hypertrophic cardiomyopathy are needed. ObjectivesThis study aims to evaluate 48-week experience from the ongoing FOREST-HCM (A Follow-Up, Open-Label, Research Evaluation of Sustained Treatment With Aficamten [CK-3773274] in Hypertrophic Cardiomyopathy) study. MethodsObstructive hypertrophic cardiomyopathy participants in an aficamten study (REDWOOD-HCM [Dose-finding Study to Evaluate the Safety, Tolerability, PK, and PD of CK-3773274 in Adults With HCM; NCT04219826]; SEQUOIA-HCM [Aficamten vs Placebo in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy; NCT05186818]) could enroll in this phase 2/3, open-label, extension study. Participants received aficamten 5 mg once daily titrated ≤20 mg based on site-read echocardiographic assessments of Valsalva left ventricular outflow tract gradient and left ventricular ejection fraction. ResultsFrom May 2021 to October 2023, 213 participants enrolled; 46 participants with 48 weeks of follow-up were evaluated (mean age: 59.7 years; female: n = 26 [56.5%]). There were rapid, substantial, and sustained reductions in mean resting (−40 ± 34 mm Hg) and Valsalva peak left ventricular outflow tract gradient (−53 ± 39 mm Hg) from baseline to week 48. A total of 82% experienced ≥1 NYHA functional class improvement; 31% experienced a 20-point improvement in Kansas City Cardiomyopathy Questionnaire–Clinical Summary score. There were substantial reductions (mean change) in maximum left ventricular wall thickness (−1.2 ± 1.6 mm; P < 0.0001), left atrial volume index (−3.5 ± 6.6 mL/m2; P = 0.0008), lateral E/e′ (−2.2 ± 6.1; P = 0.02), and cardiac biomarkers (P ≤ 0.0031). Aficamten was well tolerated with 2 (4.3%) asymptomatic and transient instances of left ventricular ejection fraction
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- University of Michigan, Ann Arbor, Michigan, USA. Electronic address: saberis@med.umich.edu.
- University of California-San Francisco, San Francisco, California, USA.
- Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
- Complexo Hospitalario Universitario A Coruña, INIBIC, CIBERCV-ISCIII, A Coruña, Spain.
- Barts Heart Centre and University College London, London, United Kingdom.
- University of Missouri Kansas City Healthcare Institute for Innovations in Quality and Saint Luke's Mid America Heart Institute, Kansas City, Missouri, USA.
Förderung
- Cytokinetics Inc
Zitieren
APA
Saberi, S., Abraham, T. P., Choudhury, L., Barriales-Villa, R., Elliott, P. M., Nassif, M. E., Oreziak, A., Owens, A. T., Tower-Rader, A., Rader, F., Garcia-Pavia, P., Olivotto, I., Coats, C. J., Fifer, M. A., Sherrid, M. V., Solomon, S. D., Watkins, H., Heitner, S. B., Jacoby, D. L., …, & FOREST-HCM Steering Committee and Investigators (2025). Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy. JACC: Heart Failure, 13(8), 102496. https://doi.org/10.1016/j.jchf.2025.03.040
Vancouver
Saberi S, Abraham TP, Choudhury L, Barriales-Villa R, Elliott PM, Nassif ME, et al. Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy. JACC: Heart Failure. 2025;13(8):102496. doi:10.1016/j.jchf.2025.03.040
BibTeX
@article{Saberi2025,
author = {Saberi, Sara and Abraham, Theodore P and Choudhury, Lubna and Barriales-Villa, Roberto and Elliott, Perry M and Nassif, Michael E and Oreziak, Artur and Owens, Anjali T and Tower-Rader, Albree and Rader, Florian and Garcia-Pavia, Pablo and Olivotto, Iacopo and Coats, Caroline J and Fifer, Michael A and Sherrid, Mark V and Solomon, Scott D and Watkins, Hugh and Heitner, Stephen B and Jacoby, Daniel L and Kupfer, Stuart and Malik, Fady I and Melloni, Chiara and Meng, Lisa and Wei, Jenny and Maron, Martin S and Masri, Ahmad and FOREST-HCM Steering Committee and Investigators, FOREST-HCM Steering Committee and Investigators},
title = {Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy},
journal = {JACC: Heart Failure},
year = {2025},
volume = {13},
number = {8},
pages = {102496},
doi = {10.1016/j.jchf.2025.03.040}
}
EUVIMED